EP Patent

EP1713477B1 — Combination of voriconazole and an antifungal cyp2c19 inhibitor

Assigned to Pfizer Ltd Great Britain · Expires 2008-10-01 · 18y expired

What this patent protects

The invention provides a therapeutic combination comprising voriconazole and an antifungal CYP2C19 inhibitor in specific quantities and weight ratios. Pharmaceutical compositions, unit dosage forms and kits comprising voriconazole and an antifungal CYP2C19 inhibitor, and their us…

USPTO Abstract

The invention provides a therapeutic combination comprising voriconazole and an antifungal CYP2C19 inhibitor in specific quantities and weight ratios. Pharmaceutical compositions, unit dosage forms and kits comprising voriconazole and an antifungal CYP2C19 inhibitor, and their use in the treatment of fungal infections, are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP1713477B1
Jurisdiction
EP
Classification
—
Expires
2008-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Ltd Great Britain
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.